Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2016 | Benefits of deacetylase inhibitors for leukemia therapy

Gesine Bug • 4 Apr 2016
EBMT 2016
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia

At the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, Gesine Bug, MD from University Hospital Frankfurt, Frankfurt/Main, Germany discusses deacetylase inhibitors, which inhibit acetylation of histones and several proteins important for cancer. These molecules need to be combined with demethylating agents or chemotherapy. They are orally available and can be used for maintenance therapy, in particular in patients after allogeneic transplantation.

More from Gesine Bug

1:04
Deacetylase inhibitors: a novel class of drugs for immune system malignancies
Gesine Bug • 4 Apr 2016
2:02
Panobinostat and donor lymphocyte infusions in patients with high-risk AML and MDS
Gesine Bug • 4 Apr 2016

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals